161 related articles for article (PubMed ID: 2461993)
1. Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells.
Press OW; Martin PJ; Thorpe PE; Vitetta ES
J Immunol; 1988 Dec; 141(12):4410-7. PubMed ID: 2461993
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ricin A chain-containing immunotoxins directed against different epitopes on the delta-chain of cell surface-associated IgD on murine B cells.
May RD; Finkelman FD; Wheeler HT; Uhr JW; Vitetta ES
J Immunol; 1990 May; 144(9):3637-42. PubMed ID: 1691764
[TBL] [Abstract][Full Text] [Related]
3. Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
Seon BK
Cancer Res; 1984 Jan; 44(1):259-64. PubMed ID: 6606488
[TBL] [Abstract][Full Text] [Related]
4. The role of ricin B chain in the intracellular trafficking of anti-CD5 immunotoxins.
Manske JM; Buchsbaum DJ; Vallera DA
J Immunol; 1989 Mar; 142(5):1755-66. PubMed ID: 2465347
[TBL] [Abstract][Full Text] [Related]
5. Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against regions I and II of the CD2 antigen.
van Lier R; Bloemena E; Brouwer M; Van Heijst J; Weinreich S; Aarden L
Immunology; 1989 Jul; 67(3):333-8. PubMed ID: 2474490
[TBL] [Abstract][Full Text] [Related]
6. High toxic efficiency of ricin immunotoxins specific for the T-cell antigen receptor of a human leukemia T-cell line.
Izquierdo M; Balboa MA; Lamana ML; López-Botet M
Int J Cancer; 1989 Apr; 43(4):697-702. PubMed ID: 2467887
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
8. Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells.
Scott CF; Bolender S; McIntyre GD; Holldack J; Lambert JM; Venkatesh YP; Morimoto C; Ritz J; Schlossman SF
J Immunol; 1989 Jun; 142(11):4105-12. PubMed ID: 2565930
[TBL] [Abstract][Full Text] [Related]
9. An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites.
Kozarsky KF; Tsai C; Bott CM; Allada G; Li LL; Fox DA
Cell Immunol; 1993 Sep; 150(2):235-46. PubMed ID: 8103706
[TBL] [Abstract][Full Text] [Related]
10. CD44 antibody against In(Lu)-related p80, lymphocyte-homing receptor molecule inhibits the binding of human erythrocytes to T cells.
Hale LP; Singer KH; Haynes BF
J Immunol; 1989 Dec; 143(12):3944-8. PubMed ID: 2480381
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the cytotoxic activity of the immunotoxins with different internalization rate.
Tonevitsky AG; Agapov II; Mechetner EB; Ershova GV; Toptygin AYu ; Sarma T; Shamshiev AT; Pfueller U
Biochem Mol Biol Int; 1993 Dec; 31(6):1059-69. PubMed ID: 8193589
[TBL] [Abstract][Full Text] [Related]
12. Selective killing of T cells by immunotoxins directed at distinct V beta epitopes of the T cell receptor.
Rigaut KD; Scharff JE; Neville DM
Eur J Immunol; 1995 Jul; 25(7):2077-82. PubMed ID: 7542605
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
[TBL] [Abstract][Full Text] [Related]
14. Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
Luo Y; Seon BK
J Immunol; 1990 Sep; 145(6):1974-82. PubMed ID: 1697314
[TBL] [Abstract][Full Text] [Related]
15. Use of colony assays and anti-T cell immunotoxins to elucidate the immunobiologic features of leukemic progenitor cells in T-lineage acute lymphoblastic leukemia.
Uckun FM; Myers DE; Ledbetter JA; Swaim SE; Gajl-Peczalska KJ; Vallera DA
J Immunol; 1988 Mar; 140(6):2103-11. PubMed ID: 3126241
[TBL] [Abstract][Full Text] [Related]
16. Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2.
Rollins SA; Kennedy SP; Chodera AJ; Elliott EA; Zavoico GB; Matis LA
Transplantation; 1994 Jun; 57(12):1709-16. PubMed ID: 7912457
[TBL] [Abstract][Full Text] [Related]
17. CD44 contributes to T cell activation.
Huet S; Groux H; Caillou B; Valentin H; Prieur AM; Bernard A
J Immunol; 1989 Aug; 143(3):798-801. PubMed ID: 2568380
[TBL] [Abstract][Full Text] [Related]
18. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
[TBL] [Abstract][Full Text] [Related]
20. Functional relationship between high-affinity E receptor and CD2-11.3 epitope.
Kontny E; Ryzewska A
Immunology; 1992 Oct; 77(2):196-200. PubMed ID: 1385311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
